Fixed combination of repaglinide and metformin in the management of type 2 diabetes
Robert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascu...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-06-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Online Access: | http://www.dovepress.com/fixed-combination-of-repaglinide-and-metformin-in-the-management-of-ty-a3289 |
| _version_ | 1797700038739099648 |
|---|---|
| author | Robert Moses |
| author_facet | Robert Moses |
| author_sort | Robert Moses |
| collection | DOAJ |
| description | Robert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascular complications. Early combination therapy with oral agents is increasingly being seen as important to achieve this. Repaglinide, a rapid-acting insulin secretagogue, targets PPG, and metformin, an insulin sensitizer, targets FBG. Because of their complementary modes of action these therapies are frequently given as combination therapy in separate tablets. To overcome the issues with adherence to multiple tablets, repaglinide and metformin are now available in a fixed-dose combination (FDC). Repaglinide/metformin FDC is bioequivalent to each tablet given separately, suggesting that the efficacy and safety profile is similar. There is no effect of food on repaglinide when in the FDC. Repaglinide/metformin FDC is as effective in reducing HbA1c and FBG whether given twice or three times daily, with a similar safety profile. Repaglinide/metformin FDC twice daily is as effective in reducing HbA1c and FBG as rosiglitazone/metformin FDC with a similar safety profile, but unlike the rosiglitazone/metformin FDC, repaglinide/metformin FDC improves the lipid profile. Repaglinide/metformin FDC represents a new option in the pursuit of achieving glucose targets and reducing vascular risk in type 2 diabetes, with the advantage of improving adherence.Keywords: type 2 diabetes, metformin, repaglinide, fixed-dose combination |
| first_indexed | 2024-03-12T04:16:23Z |
| format | Article |
| id | doaj.art-be193c0f21574bcd8f8d324553d948c1 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-03-12T04:16:23Z |
| publishDate | 2009-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-be193c0f21574bcd8f8d324553d948c12023-09-03T10:36:29ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072009-06-012009default101109Fixed combination of repaglinide and metformin in the management of type 2 diabetesRobert MosesRobert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascular complications. Early combination therapy with oral agents is increasingly being seen as important to achieve this. Repaglinide, a rapid-acting insulin secretagogue, targets PPG, and metformin, an insulin sensitizer, targets FBG. Because of their complementary modes of action these therapies are frequently given as combination therapy in separate tablets. To overcome the issues with adherence to multiple tablets, repaglinide and metformin are now available in a fixed-dose combination (FDC). Repaglinide/metformin FDC is bioequivalent to each tablet given separately, suggesting that the efficacy and safety profile is similar. There is no effect of food on repaglinide when in the FDC. Repaglinide/metformin FDC is as effective in reducing HbA1c and FBG whether given twice or three times daily, with a similar safety profile. Repaglinide/metformin FDC twice daily is as effective in reducing HbA1c and FBG as rosiglitazone/metformin FDC with a similar safety profile, but unlike the rosiglitazone/metformin FDC, repaglinide/metformin FDC improves the lipid profile. Repaglinide/metformin FDC represents a new option in the pursuit of achieving glucose targets and reducing vascular risk in type 2 diabetes, with the advantage of improving adherence.Keywords: type 2 diabetes, metformin, repaglinide, fixed-dose combinationhttp://www.dovepress.com/fixed-combination-of-repaglinide-and-metformin-in-the-management-of-ty-a3289 |
| spellingShingle | Robert Moses Fixed combination of repaglinide and metformin in the management of type 2 diabetes Diabetes, Metabolic Syndrome and Obesity |
| title | Fixed combination of repaglinide and metformin in the management of type 2 diabetes |
| title_full | Fixed combination of repaglinide and metformin in the management of type 2 diabetes |
| title_fullStr | Fixed combination of repaglinide and metformin in the management of type 2 diabetes |
| title_full_unstemmed | Fixed combination of repaglinide and metformin in the management of type 2 diabetes |
| title_short | Fixed combination of repaglinide and metformin in the management of type 2 diabetes |
| title_sort | fixed combination of repaglinide and metformin in the management of type 2 diabetes |
| url | http://www.dovepress.com/fixed-combination-of-repaglinide-and-metformin-in-the-management-of-ty-a3289 |
| work_keys_str_mv | AT robertmoses fixedcombinationofrepaglinideandmetformininthemanagementoftype2diabetes |